[{"id":"f9edf389-5ac1-4e51-b073-8c5312cec79c","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469982","created_at":"2026-03-28T01:43:35.285Z","updated_at":"2026-03-28T01:43:35.285Z","phase":"Phase 1","brief_title":"A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT07469982","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" MTAP","pipe":"","alterations":" ","tags":["MTAP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 02/01/2026","start_date":" 02/01/2026","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2026-03-13"},{"id":"92c00917-1e46-4b94-b994-56d21f87434a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04794699","created_at":"2021-03-12T16:52:33.483Z","updated_at":"2024-07-02T16:35:05.377Z","phase":"Phase 1","brief_title":"Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion","source_id_and_acronym":"NCT04794699","lead_sponsor":"IDEAYA Biosciences","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • docetaxel • albumin-bound paclitaxel • pemetrexed • Trodelvy (sacituzumab govitecan-hziy) • IDE397"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 04/14/2021","start_date":" 04/14/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 03/30/2027","study_completion_date":" 03/30/2027","last_update_posted":"2024-05-07"},{"id":"3c3237ce-b2fe-4d38-831f-297bf37b8861","acronym":"","url":"https://clinicaltrials.gov/study/NCT05312372","created_at":"2022-04-05T13:52:46.118Z","updated_at":"2024-07-02T16:35:59.449Z","phase":"Phase 1/2","brief_title":"S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC","source_id_and_acronym":"NCT05312372","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" PD-L1 • MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["PD-L1 • MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • S095033"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2022-12-07"},{"id":"d1253b91-fc27-48d4-8eda-23186b966e62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03361358","created_at":"2021-01-18T16:35:28.827Z","updated_at":"2024-07-02T16:36:48.342Z","phase":"","brief_title":"Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma","source_id_and_acronym":"NCT03361358","lead_sponsor":"Agios Pharmaceuticals, Inc.","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e S095033"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 09/30/2019","primary_completion_date":" 09/30/2019","study_txt":" Completion: 09/30/2019","study_completion_date":" 09/30/2019","last_update_posted":"2020-03-16"}]